Madrigal Pharmaceuticals, Inc. MDGL
432.60 USD -0.19 (-0.04%)
At closeNov 11, 2026, 4:01 AM EST
431.55 -1.05 -0.24%
Pre-market · Nov 11, 4:01 AM ET
424.02 Day range 443.16
353.54 52-week range 615.00
- YTD
- -25.71%
- 1 year
- -20.11%
- Market cap
- 10.05B
- Revenue (ttm)
- 1.43B
- Profit margin
- -10.89%
- EPS (ttm)
- -5.85
- Shares out
- 23.23M
- Forward P/E
- 38.59
- YTD return
- -25.71%
- 1-year return
- -20.11%
- Volume
- 459.02K
- Avg volume
- 351.69K
- Open
- 428.43
- Previous close
- 432.79
- Day's range
- 424.02 – 443.16
- 52-week range
- 353.54 – 615.00
- Beta
- -1.00
- Analysts
- Strong Buy
- Price target
- 688.94 (+59.3%)
- Earnings date
- Feb 18, 2027
5D -27.00 (-5.86%)
Key statistics
- Enterprise value
- 9.45B
- PEG ratio
- 0.00
- Price / sales
- 7.04
- Price / book
- 16.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 50.10%
- Free cash flow
- -112.43M
- Total cash
- 960.97M
- Total debt
- 354.22M
- Return on equity
- -24.82%
- Short % of float
- 11.10%
- 50-day average
- 484.73
- 200-day average
- 497.36
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 688.94 +59.3% upside
Now 432.60
- Target (low)
- 479.00
- Target (mean)
- 688.94
- Target (high)
- 962.00
Ratings (0m) 19 18 buy · 1 hold · 0 sell
- Strong buy3
- Buy15
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate 1.92.
Financials — quick view
MDGL Revenue — quarterly 431.27M
MDGL Net income — quarterly 55.44M
MDGL EPS — quarterly 1.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | 1.40 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.86315 | 1.83 | +2.69 | +312.01% |
| Jul 30, 2026 | Jun 30, 2026 | -2.68 | -1.99 | +0.69 | +25.75% |
| May 6, 2026 | Mar 31, 2026 | -3.61 | -3.25 | +0.36 | +9.97% |
| Feb 19, 2026 | Dec 31, 2025 | 0.04 | -2.57 | -2.61 | -6,525.00% |
| Nov 4, 2025 | Sep 30, 2025 | -2.04 | -5.08 | -3.04 | -149.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 4, 2026 | Truist Securities | reit | Buy | Buy |
| Nov 3, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | Citigroup | init | — | Buy |
| Aug 4, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Aug 3, 2026 | Barclays | main | Overweight | Overweight |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- madrigalpharma.com
News
MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns 
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth 
Kaplan Fox Alerts Madrigal Pharmaceuticals, Inc. (MDGL) Investors to an Investigation of Potential Securities Law Violations 
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations 
Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Lessened by Candriam S.C.A. 
Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the Firm 
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law 
MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP 
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP 
NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Your note
Sign in to keep a note on MDGL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Unknown | Stock Award(Grant) | Jun 16, 2026 | 0 |
| CRAVES FREDERICK B | Director | Sale | Mar 12, 2025 | 383,547 |
| DIER MARDI C | Chief Financial Officer | Sale | Mar 5, 2026 | 12,490 |
| FRIEDMAN PAUL A | Director | Sale | Jan 8, 2026 | 842,704 |
| HUNTSMAN CAROLE A | Officer | Sale | Mar 5, 2026 | 12,692 |
| KELLEY SHANNON T | General Counsel | Sale | Aug 16, 2026 | 11,474 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 9.23% | 2,143,131 | 927.12M | Jun 29, 2026 |
| RTW Investments LP | 8.58% | 1,993,687 | 862.47M | Jun 29, 2026 |
| Jupiter Topco LLC | 8.33% | 1,936,099 | 837.56M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 7.89% | 1,833,333 | 793.10M | Jun 29, 2026 |
| PAULSON & CO. INC. | 5.77% | 1,340,020 | 579.69M | Jun 29, 2026 |
| Blackrock Inc. | 5.17% | 1,200,770 | 519.45M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 584,997 | 253.07M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.42% | 563,117 | 243.60M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.82% | 423,142 | 183.05M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.46% | 338,602 | 146.48M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.16% | 270,288 | 116.93M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.05% | 243,683 | 105.42M | Jun 29, 2026 |